Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest
暂无分享,去创建一个
Anette Engelhardt | A. Bolmström | P. Bradford | P. Petersen | A. Engelhardt | Patricia A. Bradford | Anne Bolmström | Åsa Karlsson | Phion Ho | Peter J. Petersen | C. Hal Jones | A. Karlsson | C. Jones | P. Ho
[1] C Thornsberry,et al. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria , 1991, Journal of clinical microbiology.
[2] D. Hoban,et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). , 2005, Diagnostic microbiology and infectious disease.
[3] D. Hoban,et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004) , 2005 .
[4] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .
[5] Derek F. J. Brown,et al. Evaluation of the E test, a novel method of quantifying antimicrobial activity. , 1991, The Journal of antimicrobial chemotherapy.
[6] M. Roberts. Tetracycline therapy: update. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] N. Jacobus,et al. In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.
[8] P. Bradford,et al. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] E. Goldstein,et al. Evaluation of the E test for susceptibility testing of anaerobic bacteria , 1991, Journal of clinical microbiology.
[10] J. O'Connell,et al. Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test Method , 2005, Antimicrobial Agents and Chemotherapy.
[11] E. Loh,et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[13] A. Yamaguchi,et al. Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936) , 2004, Antimicrobial Agents and Chemotherapy.
[14] E. Loh,et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[16] W. J. Novick. Development of in vitro susceptibility testing criteria and quality control parameters , 1989 .
[17] A. Howe,et al. Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure Infections , 2006, Antimicrobial Agents and Chemotherapy.
[18] P. Bradford,et al. Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.